Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00337194 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-30 / ADCETRIS®)

Study Title
SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT00337194)

Trial Description
This randomized phase II trial studies the side effects and how well giving monoclonal antibody SGN-30 together with combination chemotherapy works in treating patients with Hodgkin lymphoma that has returned after a period of improvement or did not respond to previous treatment. Monoclonal antibodies, including antibody-drug conjugates such as SGN-30, may interfere with the ability of cancer cells to grow and spread.

Drugs used in chemotherapy, such as gemcitabine hydrochloride, vinorelbine tartrate, and pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving monoclonal antibody SGN-30 together with combination chemotherapy may kill more cancer cells and shrink tumors.

This trial is sponsored by National Cancer Institute (NCI). [1]

Study Data

  • Condition:
  • Interventions:
  • Phase: II
  • Enrollment: 30
  • Start: April 2006
  • Completion: October 2014
  • Last verified: October 2014

Study Schematic

NCT00337194 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-30 / ADCETRIS®)

Click here to Return to Drug map


Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar